Drug Therapy

  • Psychogenic nonepileptic seizure: An empathetic, practical approach
    Becky Bikat S. Tilahun, PhD and Jocelyn F. Bautista, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 252-259; DOI: https://doi.org/10.3949/ccjm.89a.21109

    Barriers to care include clinician misperceptions, lack of acceptance of the diagnosis, poor patient engagement with treatment, and lack of access to care.

  • Psychogenic nonepileptic seizure: A neurologist’s perspective
    Elaine Wyllie, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 260-261; DOI: https://doi.org/10.3949/ccjm.89a.21129

    Confirming the diagnosis is only the start of the journey. The greater challenge and opportunity lie in how physicians present the diagnosis to the patient and family.

  • Esophageal adenocarcinoma: A dire need for early detection and treatment
    Esophageal adenocarcinoma: A dire need for early detection and treatment
    Abel Joseph, MD, Siva Raja, MD, PhD, Suneel Kamath, MD, Sunguk Jang, MD, Daniela Allende, MD, Mike McNamara, MD, Gregory Videtic, MD, Sudish Murthy, MD and Amit Bhatt, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 269-279; DOI: https://doi.org/10.3949/ccjm.89a.21053

    A clinical overview focused on screening, multidisciplinary evaluation, and treatment of early esophageal adenocarcinoma.

  • Treating anemia: It’s not just the EPO
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 174-175; DOI: https://doi.org/10.3949/ccjm.89b.04022

    Long-term effects of treatment with the new oral inhibitors of prolyl hydroxylase will need to be carefully monitored, as prolyl hydroxylase is a key structural component of diverse proteins.

  • Oral hyperpigmentation with weakness and salt-craving
    Joseph Zhou, MD and S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 180-181; DOI: https://doi.org/10.3949/ccjm.89a.21036

    The patient’s primary care physician had attributed the hyperpigmentation on the lower lip and inner cheek to pen ink.

  • Glycemic targets in the ICU: A look back, and ahead
    Keren Zhou, MD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 189-190; DOI: https://doi.org/10.3949/ccjm.89a.21127

    Much work is still needed to understand the nuances of glycemic targets in critically ill patients, and to learn how to take advantage of evolving technology to improve glycemic control.

  • Glycemic control in the critically ill: Less is more
    Ghaith Alhatemi, MD, Haider Aldiwani, MD, Rafal Alhatemi, MD, Marwah Hussein, MD, Suzan Mahdai, MD and Berhane Seyoum, MD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 191-199; DOI: https://doi.org/10.3949/ccjm.89a.20171

    The authors discuss findings from key trials, metrics of glycemic control, and recommendations of professional societies for target blood glucose ranges in critically ill patients.

  • Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Tarek Souaid, MD, Jonathan Taliercio, DO, James F. Simon, MD, MBA, Ali Mehdi, MD, MEd and Georges N. Nakhoul, MD, MEd
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 212-222; DOI: https://doi.org/10.3949/ccjm.89a.21100

    A review of the pathophysiology of anemia of chronic kidney disease, major clinical trials, and novel therapies.

  • Extraosseous calcification in kidney disease
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 223;

    The following article in the February 2022 issue contained an error: Bartolomeo K, Tan XY, Fatica R. Extraosseous calcification in kidney disease. Cleve Clin J Med 2022; 89(2):81–90. doi:10.3949/ccjm.89a.21073

  • Potential systemic benefits of shocking or blocking nerves
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 119-120; DOI: https://doi.org/10.3949/ccjm.89b.03022

    What has really caught my attention is the expanding research on controlled regional neuromodulation and its impact on systemic physiology and inflammation.

Pages